This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix reports third-quarter net loss of $7.3 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix reported a third-quarter net loss of approximately $7.3 million, or $0.48 per share, compared with a net loss of $3.5 million, or $1.34 per share, in the same quarter last year, according to a press release.

Total operating expenses were $6.9 million, compared with $3.4 million a year ago.

Research and development expenses totaled $4.5 million, compared with $2.8 million last year. The company attributed this increase to clinical trials of OTX-DP for the treatment of allergic conjunctivitis and postoperative ocular inflammation and pain and OTX-TP for the treatment of glaucoma and ocular hypertension.

ReSure sealant, which went on sale in the first quarter, generated $143,000 in revenue.